학술논문
Emergence and evolution of TP53 mutations are key features of disease progression in myelodysplastic patients with lower-risk del(5q) treated with lenalidomide
Document Type
Artikel
Author
Source
Haematologica. 103(4):E143-E146
Subject
Language
English
English
English
ISSN
1592-8721